Masimo Co. (NASDAQ:MASI) Shares Sold by New York State Teachers Retirement System

New York State Teachers Retirement System decreased its holdings in shares of Masimo Co. (NASDAQ:MASI) by 4.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 50,548 shares of the medical equipment provider’s stock after selling 2,500 shares during the period. New York State Teachers Retirement System owned approximately 0.10% of Masimo worth $5,925,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the business. Massmutual Trust Co. FSB ADV lifted its position in Masimo by 140.6% in the fourth quarter. Massmutual Trust Co. FSB ADV now owns 243 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 142 shares during the period. DHJJ Financial Advisors Ltd. acquired a new stake in Masimo in the third quarter valued at about $32,000. NBC Securities Inc. acquired a new stake in Masimo in the third quarter valued at about $34,000. Caisse DE Depot ET Placement DU Quebec acquired a new stake in Masimo in the first quarter valued at about $37,000. Finally, Belpointe Asset Management LLC lifted its position in Masimo by 31.4% in the first quarter. Belpointe Asset Management LLC now owns 339 shares of the medical equipment provider’s stock valued at $63,000 after purchasing an additional 81 shares during the period. Institutional investors and hedge funds own 85.96% of the company’s stock.

Masimo Price Performance

MASI stock opened at $137.92 on Friday. The firm has a 50 day moving average of $135.41 and a 200-day moving average of $112.49. Masimo Co. has a 12-month low of $75.22 and a 12-month high of $198.00. The company has a current ratio of 2.18, a quick ratio of 1.22 and a debt-to-equity ratio of 0.64. The company has a market cap of $7.30 billion, a price-to-earnings ratio of 91.34 and a beta of 0.97.

Masimo (NASDAQ:MASI) last issued its quarterly earnings data on Tuesday, February 27th. The medical equipment provider reported $1.25 earnings per share for the quarter, topping analysts’ consensus estimates of $0.82 by $0.43. Masimo had a net margin of 3.98% and a return on equity of 13.77%. The business had revenue of $548.90 million during the quarter, compared to analysts’ expectations of $545.69 million. During the same period last year, the company posted $1.32 EPS. The company’s revenue was down 11.0% on a year-over-year basis. As a group, equities analysts expect that Masimo Co. will post 3.51 EPS for the current fiscal year.

Analysts Set New Price Targets

MASI has been the subject of a number of recent analyst reports. BTIG Research raised their price objective on shares of Masimo from $145.00 to $166.00 and gave the company a “buy” rating in a research report on Monday, March 25th. Jefferies Financial Group restated a “hold” rating and issued a $121.00 price objective (up previously from $107.00) on shares of Masimo in a research report on Tuesday, January 30th. Wells Fargo & Company upgraded shares of Masimo from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $117.00 to $160.00 in a research report on Monday, March 25th. Stifel Nicolaus lifted their price target on shares of Masimo from $125.00 to $148.00 and gave the company a “hold” rating in a research report on Monday, March 25th. Finally, Piper Sandler lifted their price target on shares of Masimo from $70.00 to $117.00 and gave the company a “neutral” rating in a research report on Monday, February 26th. Six investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, Masimo currently has an average rating of “Hold” and a consensus target price of $134.29.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.